See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Two Divergent Approaches to Drugging IRF5

Summary by Drug Hunter
Targeting transcription factors for therapeutic intervention is a challenge in small molecule drug discovery. However excitement around IRF5, a key immune system regulator that is implicated in lupus and rheumatoid arthritis, has inspired renewed effort. This review highlights how two companies, HotSpot Therapeutics and Kymera Therapeutics, are tackling IRF5 with distinct strategies. Both approaches show promise by reducing inflammation and dise…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Drug HunterDrug Hunter

Two Divergent Approaches to Drugging IRF5

Targeting transcription factors for therapeutic intervention is a challenge in small molecule drug discovery. However excitement around IRF5, a key immune system regulator that is implicated in lupus and rheumatoid arthritis, has inspired renewed effort. This review highlights how two companies, HotSpot Therapeutics and Kymera Therapeutics, are tackling IRF5 with distinct strategies. Both approaches show promise by reducing inflammation and dise…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Drug Hunter broke the news in on Tuesday, July 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal